INTRODUCTION

Epstein-Barr virus (EBV)
,
MATERIALS AND METHODS
Standard medium for cell culture was RPMI 1640 (high glutamine, Gibco)
supplemented with 10% FCS (PAA), 1% Penicillin/Streptomycin (Gibco), and 100 nM sodium selenite (ICN). For continuous culture of EBV producer cell lines, hygromycin 5 (75 g/mL; PAA) was added. When noted, cyclosporin A (1 g/mL; Novartis) was used in PBMC or B cell infections.
Production of recombinant EBV and virus-like particles.
Transforming EBV was produced in a cell line (2089/293) based on 293 cells stably transduced with a GFPencoding recombinant EBV genome based on EBV strain B95. 8 (14) . EBV genome-10 free virus-like particles were produced in a cell line (TR-/293) carrying a GFPencoding EBV genome deleted for the terminal repeats (TR), EBV's essential cisacting packaging signals (15) . For virus or virus-like particle production, cells were plated in medium without hygromycin, and EBV's lytic cycle was transiently induced by transfection with an expression plasmid coding for BZLF1 using Metafectene 15 transfection reagent (Biontex). Supernatants containing virus ("EBV") or virus-like particles ("EBV TR-") were harvested three days later and further purified by centrifugation of cell debris (300 g, 5 min) and filtration (0,8 m pore size). EBV or EBV TR-preparations were stored at 4°C for up to 3 months. Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocols.
Purified B cell preparations regularly contained >98% CD20+ cells, as assessed by flow cytometry. Naive (CD27-) and memory (CD27+) B cells were separated by labeling with anti-human CD27 microbeads and two consecutive purifications using paramagnetic MS columns (Miltenyi Biotech). The purity of the subpopulations was 5 assessed by flow cytometry. (Fig. 3C) . However, the relative potential of initial CpG treatment to rescue B cell outgrowth was even greater for delayed EBV infection than for simultaneous infection. For example, when EBV infection was delayed for one day, CpG-pretreated B cells yielded 10 times more lymphoblastoid 5 cells than medium-pretreated cells (Fig. 3C ).
To test whether other immune effector cells could influence this EBV-CpG synergism, we repeated the experiment with total PBMC, instead of purified B cells, in the presence or absence of cyclosporin A, an inhibitor of T cell activation. PBMCs from EBV-positive donors were used, in order to detect a possible effect of EBV-specific 10 memory T cells. However, the effect of CpG DNA on EBV-mediated lymphoblastoid cell outgrowth from PBMCs ( Fig. 3D ) and from purified B cells (Fig. 3A) was very similar, and inhibition of T cell activation by cyclosporin A had no effect (Fig. 3D ). Depletion of available IL-6 or IL-10 by blocking antibodies had no effect on lymphoblastoid cell outgrowth in the early days after infection, neither after EBV infection alone nor after infection in the presence of CpG DNA ( Figure 4D, E) . These results are in line with previous observations that IL-10 depletion does not strongly 15 reduce outgrowth of EBV-infected B cells during the first 7 days after infection, but only later (9), when cell density is higher or cytokine accumulates over time in vitro.
We conclude that the enhanced IL-6 or IL-10 release is not a major factor in the rapid CpG DNA-mediated increase of outgrowth in the first days after EBV infection. (Fig. 7) ; only BALF4, a glycoprotein that is produced at low amounts, limiting infectivity of some EBV strains (42), was occasionally upregulated by CpG DNA. However, alterations by CpG treatment were limited and 20 did not exceed a 2-fold upregulation or 3.5-fold downregulation. In contrast, when we tested whether supernatants of these LCLs contained EBV that could infect and transform a sensitive B cell line, we obtained transformants exclusively with supernatants from CpG-treated, not from untreated LCLs (Table 1) 
